With KidneyIntelX™, clinicians and health systems are

Take Control

Manage CKD in stages 1-3 through a PCP-driven approach

Take Control

Through reliable & actionable risk stratification

Take Control

Make better decisions as to which patients can benefit most from therapeutics

Take Control

By deploying resources most efficiently: only the right patients referred to nephrology

Take Control

Drive improved quality of care and HEDIS metrics

Take Control

Better manage ACO, VBC and risk contracts by improving preemptive, upstream care.

KidneyIntelX is the
one test that helps PCPs make more informed decisions.

KidneyIntelX is the only bioprognostic methodology for demonstrated risk assessment of adult patients with type 2 diabetes and chronic kidney disease stages 1-3.

  • Low scoring patients have an approximate 90% chance of not experiencing DKD progression1,2
  • High scoring patients have an approximate 70% chance of experiencing DKD progression1